Search results
May 24, 2022 · In this review we discuss recent progress of the three most advanced DENV vaccines (Dengvaxia ®, TV003/TV005, and TAK-003) (Table (Table2),2), focusing on the molecular characteristics of each vaccine (Fig. (Fig.1)1) and the available clinical data on their efficacy and immunogenicity.
- 10.1007/s40259-022-00531-z
- 2022
- BioDrugs. 2022; 36(3): 325-336.
Jan 31, 2024 · Abstract. In 2019, the four serotypes of the mosquito-borne dengue virus (DENV) caused an estimated 56 million cases of disease and 5000 to 40,000 deaths in a global swath of tropical and near ...
May 10, 2024 · There is a growing public health need for effective preventive interventions against dengue, a disease caused by four viruses, termed serotypes 1–4. Two dengue vaccines have been licensed, Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur, and Qdenga® (TAK-003), developed by Takeda.
- CYD-TDV is the first dengue vaccine to be licensed. It was first licensed in Mexico in December 2015 for use in individuals 9-45 years of age livin...
- CYD-TDV has been evaluated in two Phase 3 clinical trials (CYD14 in five countries in Asia and CYD15 in five countries in Latin America). Together,...
- The new analyses from the long-term safety follow-up indicated that: Overall population level benefit of vaccination remains favorable, but the vac...
- Following the release of the long-term safety data stratified by serostatus on 29 November 2017, a SAGE working group on dengue vaccines was reconv...
- CYD-TDV is currently not prequalified. Prequalification requires an NRA of record, which is typically the NRA in the manufacturing country (in this...
- Vector control has been the key strategy to control or prevent the transmission of dengue virus. Strategies include: preventing mosquitoes from acc...
Mar 29, 2022 · Few dengue vaccine formulations that are based on non-structural proteins are being investigated in clinical trials. Modern vaccine platforms, such as those based on RNA for COVID-19, would be ideal to test the possibility of controlling dengue virus using only non-structural proteins as antigens.
Jan 31, 2024 · Butantan–Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine against dengue disease, but data on its overall efficacy are needed.
Apr 15, 2023 · Abstract. Dengue is a major global public health problem requiring a safe and efficacious vaccine as the foundation of a comprehensive countermeasure strategy. Despite decades of attempts, the...
Introduction: Dengue virus is a global health threat, with approximately 390 million dengue infections annually. Efficient vaccines for dengue prevention are currently lacking. This review aims to summarize the current progress in dengue vaccine development.
